Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

by Vandana Singh, Benzinga Editor

June 15, 2021 6:07 AM | 27 seconds read | Make a Comment

Daiichi Sankyo Co Ltd DSNKY said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason.
However, the Nikkei newspaper reported that there were safety concerns.
In March, the company started a Phase 1 trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients.
Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
Price Action: DSNKY closed at $23.76 on Monday.

Posted In: Biotech News Health Care General Briefs Covid-19 COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.